RIGL

Rigel Pharmaceuticals, Inc. NASDAQ

Healthcare ·Biotechnology ·US · rigel.com

$29.54

Mkt Cap $545.9M

52w Low $16.88 35.8% of range 52w High $52.24

50d MA $29.57 200d MA $34.16

P/E (TTM) 1.4x

EV/EBITDA 6.1x

P/B 1.4x

Debt/Equity 0.1x

ROE 93.8%

P/FCF 10.2x

RSI (14) —

ATR (14) —

Beta 1.27

50d MA $29.57

200d MA $34.16

Avg Volume 349.2K

About

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 3, 2026	AMC	1.33	1.14	-14.3%	33.02	-8.3%	-10.3%	-10.6%	-12.6%	-15.0%	-13.9%	—
Nov 4, 2025	AMC	0.93	1.46	+57.0%	28.38	+22.9%	+33.4%	+27.3%	+24.0%	+21.7%	+33.7%	—
Aug 5, 2025	AMC	1.97	3.28	+66.5%	24.24	+12.1%	+23.0%	+25.6%	+30.8%	+38.0%	+42.4%	—
May 6, 2025	AMC	0.14	0.63	+350.0%	18.26	+23.5%	+1.2%	+3.5%	+2.8%	+1.9%	+0.2%	—
Mar 4, 2025	AMC	0.30	0.80	+166.7%	22.08	-8.7%	-8.1%	-10.8%	-7.1%	-11.5%	-11.7%	—
Nov 7, 2024	AMC	0.06	0.70	+1066.7%	15.44	+7.8%	+42.9%	+61.6%	+76.3%	+77.5%	+77.8%	—
Aug 6, 2024	AMC	-0.37	-0.06	+83.8%	9.33	+12.5%	+5.8%	+11.8%	+9.4%	+20.6%	+35.8%	—
May 7, 2024	AMC	-0.30	-0.50	-66.7%	11.90	-6.7%	-16.6%	-14.3%	-17.3%	-17.5%	-20.3%	—
Mar 5, 2024	AMC	0.02	0.04	+99.9%	14.80	+4.1%	+5.4%	+3.4%	+6.1%	+2.0%	+0.7%	—
Nov 7, 2023	AMC	-0.70	-0.30	+57.1%	8.71	+3.3%	+2.2%	-6.2%	-6.1%	-8.0%	-2.4%	—
Aug 1, 2023	AMC	-0.80	-0.40	+50.0%	13.30	+1.5%	-3.0%	-5.3%	-8.3%	-10.5%	-12.0%	—
May 2, 2023	AMC	-0.90	-0.80	+11.1%	11.40	-1.8%	+0.9%	+2.6%	+3.5%	+4.4%	+1.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Nov 5	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$28.38	$34.87	+22.9%	+33.4%	+27.3%	+24.0%	+21.7%	+33.7%
Nov 5	Jefferies	Upgrade	Hold → Buy	—	$28.38	$34.87	+22.9%	+33.4%	+27.3%	+24.0%	+21.7%	+33.7%
Oct 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$29.50	$30.25	+2.5%	-2.5%	-3.7%	-4.5%	-9.1%	-7.2%
Aug 6	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$24.24	$27.18	+12.1%	+23.0%	+25.6%	+30.8%	+38.0%	+42.4%
May 7	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$18.26	$22.55	+23.5%	+1.2%	+3.5%	+2.8%	+1.9%	+0.2%
Mar 6	Citigroup	Maintains	Buy → Buy	—	$20.29	$20.28	-0.0%	-2.9%	+1.1%	-3.7%	-3.9%	+0.7%
Mar 5	B. Riley Securities	Maintains	Neutral → Neutral	—	$22.08	$20.15	-8.7%	-8.1%	-10.8%	-7.1%	-11.5%	-11.7%
Mar 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.08	$20.15	-8.7%	-8.1%	-10.8%	-7.1%	-11.5%	-11.7%
Jan 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.81	$21.57	-1.1%	+1.5%	+1.7%	-0.4%	+1.6%	+3.1%
Jan 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.81	$22.02	+1.0%	+0.0%	+1.5%	+1.7%	-0.4%	+1.6%
Jan 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.11	$17.22	+0.6%	-2.5%	+5.3%	+1.4%	+17.7%	+27.5%
Dec 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.16	$22.37	-3.4%	-11.2%	-15.7%	-17.9%	-18.4%	-17.4%
Dec 10	B. Riley Securities	Maintains	Neutral → Neutral	—	$23.16	$22.37	-3.4%	-11.2%	-15.7%	-17.9%	-18.4%	-17.4%
Dec 10	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$23.16	$22.37	-3.4%	-11.2%	-15.7%	-17.9%	-18.4%	-17.4%
Dec 6	B. Riley Securities	Maintains	Neutral → Neutral	—	$26.03	$26.22	+0.7%	-2.2%	-11.0%	-21.0%	-25.0%	-27.0%
Nov 14	Piper Sandler	Maintains	Neutral → Neutral	—	$27.41	$27.80	+1.4%	+0.2%	-12.1%	-17.0%	-12.8%	-11.3%
Nov 12	Citigroup	Maintains	Buy → Buy	—	$24.95	$25.00	+0.2%	+9.1%	+9.9%	+10.1%	-3.4%	-8.9%
Oct 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.43	$14.43	+0.0%	-1.9%	+0.6%	-0.6%	-1.1%	-5.5%
Aug 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.43	$10.50	+0.7%	-2.1%	+7.9%	+21.5%	+14.8%	+19.6%
Jun 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.56	$9.00	-5.9%	-11.8%	-17.4%	-0.3%	-14.0%	-12.0%
Jun 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.53	$9.50	-0.3%	-2.8%	-5.2%	+0.2%	-0.3%	+0.3%
Jun 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.78	$10.00	+2.2%	+0.5%	-0.3%	-0.1%	-1.8%	-2.9%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.90	$11.10	-6.7%	-16.6%	-14.3%	-17.3%	-17.5%	-20.3%
Mar 7	Citigroup	Maintains	Buy → Buy	—	$15.60	$15.90	+1.9%	-1.9%	+0.6%	-3.2%	-4.5%	-7.1%
Mar 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.80	$15.40	+4.1%	+5.4%	+3.4%	+6.1%	+2.0%	+0.7%
Mar 6	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$14.80	$15.40	+4.1%	+5.4%	+3.4%	+6.1%	+2.0%	+0.7%
Mar 6	B. Riley Securities	Maintains	Neutral → Neutral	—	$14.80	$15.40	+4.1%	+5.4%	+3.4%	+6.1%	+2.0%	+0.7%
Feb 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.20	$12.10	+8.0%	+16.1%	+17.9%	+26.8%	+33.9%	+38.4%
Jan 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.50	$14.90	+2.8%	+2.8%	-4.8%	+2.1%	-5.5%	-6.2%
Dec 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.40	$11.70	+2.6%	+16.2%	+12.3%	+9.6%	+14.0%	+12.3%
Aug 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.30	$13.50	+1.5%	-3.0%	-5.3%	-8.3%	-10.5%	-12.0%
May 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.40	$11.20	-1.8%	+0.9%	+2.6%	+3.5%	+4.4%	+1.8%
Mar 9	Citigroup	Maintains	Buy → Buy	—	$17.90	$18.00	+0.6%	-6.1%	-11.5%	-11.7%	-10.1%	-6.1%
Mar 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.70	$18.10	+23.1%	+21.8%	+14.3%	+7.8%	+7.5%	+9.5%
Dec 2	Citigroup	Upgrade	Neutral → Buy	—	$6.84	$9.39	+37.3%	+21.9%	+38.9%	+34.8%	+30.8%	+31.1%
Nov 4	BMO Capital	Maintains	Outperform → Outperform	—	$7.26	$7.53	+3.7%	+1.9%	+2.8%	+0.6%	-7.7%	-1.0%
Aug 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.90	$17.30	+8.8%	+1.9%	-4.4%	-6.3%	+8.2%	+3.8%
Aug 17	Piper Sandler	Maintains	Neutral → Neutral	—	$15.60	$15.40	-1.3%	+1.9%	+3.8%	-2.6%	-4.5%	+10.3%
Jun 9	B. Riley Securities	Maintains	Neutral → Neutral	—	$7.01	$7.37	+5.1%	+2.4%	-4.0%	-1.1%	+4.6%	+16.3%
Jun 9	BMO Capital	Maintains	Outperform → Outperform	—	$7.01	$7.37	+5.1%	+2.4%	-4.0%	-1.1%	+4.6%	+16.3%
Jun 9	Citigroup	Downgrade	Buy → Neutral	—	$7.01	$7.37	+5.1%	+2.4%	-4.0%	-1.1%	+4.6%	+16.3%
Jun 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.60	$8.88	-49.5%	-60.2%	-59.2%	-61.8%	-60.6%	-58.4%
Jun 8	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$17.60	$8.88	-49.5%	-60.2%	-59.2%	-61.8%	-60.6%	-58.4%
Mar 23	B. Riley Securities	Maintains	Neutral → Neutral	—	$33.40	$32.90	-1.5%	-7.5%	-1.8%	-4.8%	-6.3%	-6.3%
Feb 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$45.30	$53.20	+17.4%	+5.1%	+2.9%	+1.8%	-9.9%	-3.5%
Nov 9	JP Morgan	Downgrade	Overweight → Neutral	—	$26.20	$24.90	-5.0%	-0.4%	+4.6%	+5.3%	+1.9%	+5.0%
Aug 6	Citigroup	Maintains	Buy → Buy	—	$25.20	$25.00	-0.8%	-2.4%	+2.4%	+3.2%	+0.8%	-0.8%
May 27	JP Morgan	Maintains	Overweight → Overweight	—	$19.80	$19.90	+0.5%	+3.0%	+2.5%	-1.3%	-2.5%	-0.5%
Dec 9	BMO Capital	Maintains	Outperform → Outperform	—	$21.70	$21.20	-2.3%	-0.5%	+3.5%	+5.1%	+4.1%	+2.8%
Nov 15	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$22.90	$23.20	+1.3%	+2.2%	-1.7%	-0.9%	+2.6%	-2.2%

Recent Filings

8-K · 1.02 !! High

Rigel Pharmaceuticals Inc. (New) -- 8-K 1.02: Material Agreement Terminated

Rigel Pharmaceuticals terminated its CNS disease program effective June 15, 2026, eliminating a potential revenue stream and narrowing its pipeline focus to other therapeutic areas.

Apr 21

8-K

Rigel Pharmaceuticals Inc. (New) -- 8-K Filing

Rigel Pharmaceuticals reported Q4 2025 revenue from three marketed drugs—TAVALISSE, GAVRETO, and REZLIDHIA—demonstrating progress in its hematologic disorders and cancer portfolio.

Mar 3

8-K · 5.02 !!! Very High

Rigel Pharmaceuticals Inc. (New) -- 8-K 5.02: Executive Change

Rigel Pharmaceuticals appointed Michael P. Miller as a director, potentially strengthening its board governance and oversight capabilities.

Feb 3

Data updated apr 26, 2026 10:48pm · Source: massive.com